Patents by Inventor Henning Thøgersen
Henning Thøgersen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20190367578Abstract: The present invention relates to novel peptides that are derivatives of glucose-dependent insulinotropic polypeptide (GIP) analogues having improved physical stability in solution and a protracted profile of action. More particular the invention relates to such peptides that are agonists at the GIP receptor and to their use in weight management or for treatment of diseases such as obesity, diabetes or non-alcoholic steatohepatitis (NASH).Type: ApplicationFiled: May 3, 2019Publication date: December 5, 2019Inventors: Wouter Frederik Johan Hogendorf, Henning Thoegersen, Nicholas Raymond Cox, Patrick J. Knerr, Richard DiMarchi, Brian Finan, Jesper F. Lau, Steffen Reedtz-Runge, Fa Liu
-
Patent number: 10398782Abstract: The invention relates to MIC-1 compounds. More specifically it relates to compounds comprising a MIC-1 polypeptide with an N-terminal amino acid extension and a protractor wherein the amino acid extension comprises 3 to 36 amino acid residues and where the MIC-1 polypeptide and the N-terminal amino acid extension together have a calculated pI lower than 6.5. The compounds of the invention have MIC-1 activity. The invention also relates to pharmaceutical compositions comprising such compounds and pharmaceutically acceptable excipients, as well as the medical use of the compounds.Type: GrantFiled: May 23, 2018Date of Patent: September 3, 2019Assignee: Novo Nordisk A/SInventors: Xiang Gao, Xujia Zhang, Hongtao Guan, Henning Thoegersen, Kristian Sass-Oerum, Lars Fogh Iversen, Per Noergaard, Sebastian Beck Joergensen, Kristian Tage Hansen, Yi Wang, Kilian Waldemar Conde Frieboes, Birgit Wieczorek
-
Publication number: 20190248852Abstract: The invention relates to MIC-1 compounds. More specifically it relates to compounds comprising a MIC-1 polypeptide and an N-terminal amino acid extension, wherein said extension consists of 3 to 36 amino acid residues and where the compound has a calculated pI lower than 6.5. The compounds of the invention have MIC-1 activity. 5 The invention also relates to pharmaceutical compositions comprising such compounds and pharmaceutically acceptable excipients, as well as the medical use of the compounds.Type: ApplicationFiled: May 24, 2017Publication date: August 15, 2019Applicants: Novo Nordisk A/S, Novo Nordisk A/SInventors: Xujia Zhang, Xiang Gao, Hongtao Guan, Henning Thoegersen, Kristian Sass-Oerum, Lars Fogh Iversen, Per Noergaard, Sebastian Beck Joergensen, Kristian Tage Hansen, Yi Wang
-
Publication number: 20190016768Abstract: The invention relates to compounds derived from the EGF(A) domain of LDL-R, in particular compounds comprising a peptide analogue of the wild-type EGF(A) (LDL-R(293-332)) sequence and at least one substituent comprising at least one fatty acid group. The invention also relates to a pharmaceutical composition thereof and use a medicament. The novel EGF(A) compounds of the invention are useful as treatment e.g. in the field of cholesterol lowering, dyslipidaemia and cardiovascular disease.Type: ApplicationFiled: January 13, 2017Publication date: January 17, 2019Inventors: Jianhe Chen, Jesper F. Lau, Janos Tibor Kodra, Birgit Wieczorek, Lars Linderoth, Henning Thoegersen, Salka Elboel Rasmussen, Patrick William Garibay
-
Publication number: 20180339057Abstract: The invention relates to MIC-1 compounds. More specifically it relates to compounds comprising a MIC-1 polypeptide with an N-terminal amino acid extension and a protractor wherein the amino acid extension comprises 3 to 36 amino acid residues and where the MIC-1 polypeptide and the N-terminal amino acid extension together have a calculated pI lower than 6.5. The compounds of the invention have MIC-1 activity. The invention also relates to pharmaceutical compositions comprising such compounds and pharmaceutically acceptable excipients, as well as the medical use of the compounds.Type: ApplicationFiled: May 23, 2018Publication date: November 29, 2018Inventors: Xiang Gao, Xujia Zhang, Hongtao Guan, Henning Thoegersen, Kristian Sass-Oerum, Lars Fogh Iversen, Per Noergaard, Sebastian Beck Joergensen, Kristian Tage Hansen, Yi Wang, Kilian Waldemar Conde Frieboes, Birgit Wieczorek
-
Patent number: 9988430Abstract: New GLP-1 derivatives, compositions thereof and their use in medicine.Type: GrantFiled: October 9, 2015Date of Patent: June 5, 2018Assignee: Novo Nordisk A/SInventors: Steffen Reedtz-Runge, Ulrich Sensfuss, Thomas Kruse, Jane Spetzler, Henning Thoegersen, Christian W. Tornoee, Jesper F. Lau
-
Patent number: 9956264Abstract: The invention relates to MIC-1 fusion proteins. More specifically it relates to compounds comprising fusion proteins comprising a MIC-1 protein or an analog thereof at the C-terminus of the fusion protein and a functional variant of human serum albumin at the N-terminus of the fusion protein connected via a peptide linker. The compounds of the invention have MIC-1 activity. The invention also relates to pharmaceutical compositions comprising such compounds and pharmaceutically acceptable excipients, as well as the medical use of the compounds.Type: GrantFiled: January 19, 2016Date of Patent: May 1, 2018Assignee: Novo Nordisk A/SInventors: Allan C. Shaw, Charlotte Helgstrand, Michael P. Bastner Sandrini, Sebastian B. Joergensen, Henning Thoegersen, Kristian Sass-Oerum, Sven Hastrup, Kim V. Andersen
-
Publication number: 20180016319Abstract: The present invention relates to novel peptide compounds which have an improved physical stability in solution and improved solubility at neutral pH, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of hyperglycemia, diabetes and obesity, as well as a variety of diseases or conditions associated with hyperglycemia, diabetes and obesity.Type: ApplicationFiled: July 26, 2017Publication date: January 18, 2018Inventors: Jesper F. Lau, Thomas Kruse, Lars Linderoth, Henning Thoegersen
-
Publication number: 20170190757Abstract: The present invention relates to novel peptide compounds which have a protracted profile of action and improved solubility and stability, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of hyperglycemia, diabetes and obesity, as well as a variety of diseases or conditions associated with hyperglycemia, diabetes and obesity.Type: ApplicationFiled: March 13, 2017Publication date: July 6, 2017Inventors: Jesper F. Lau, Thomas Kruse, Lars Linderoth, Henning Thoegersen, Jacob Kofoed, Kirsten Dahl
-
Patent number: 9655974Abstract: Analogs of FGF21 carrying a modifying, substituted ethylene or benzyl group can be used for treatment or prevention of diabetes, dyslipidemia, obesity, cardiovascular diseases, metabolic syndrome, and/or Non Alcoholic Fatty Liver Disease (NAFLD).Type: GrantFiled: July 18, 2011Date of Patent: May 23, 2017Assignee: Novo Nordisk A/SInventors: Tina Moeller Tagmose, Patrick William Garibay, Xujia Zhang, Henning Thoegersen, Peter Kresten Nielsen, Kristian Sass Bak-Jensen, Helle Fabricius Woeldike
-
Publication number: 20170051034Abstract: The present invention relates to novel peptide compounds which have a protracted profile of action and improved solubility and stability, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of hyperglycemia, diabetes and obesity, as well as a variety of diseases or conditions associated with hyperglycemia, diabetes and obesity.Type: ApplicationFiled: September 12, 2016Publication date: February 23, 2017Inventors: Jesper F. Lau, Thomas Kruse, Lars Linderoth, Henning Thoegersen, Jacob Kofoed, Kirsten Dahl
-
Publication number: 20160347812Abstract: The present invention relates to novel glucagon peptides, to the use of said glucagon peptides in therapy, to methods of treatment comprising administration of said glucagon peptides to patients in need thereof, and to the use of said glucagon peptides in the manufacture of medicaments. The glucagon peptides of the present invention are of particular interest in relation to the treatment of hyperglycemia, diabetes and obesity, as well as a variety of diseases or conditions associated with hyperglycemia, diabetes and obesity.Type: ApplicationFiled: August 16, 2016Publication date: December 1, 2016Inventors: Jesper F. Lau, Thomas Kruse, Henning Thoegersen, Ulrich Sensfuss, Peter Kresten Nielsen
-
Patent number: 9486506Abstract: The present invention relates to novel glucagon peptides, to the use of said glucagon peptides in therapy, to methods of treatment comprising administration of said glucagon peptides to patients in need thereof, and to the use of said glucagon peptides in the manufacture of medicaments. The glucagon peptides of the present invention are of particular interest in relation to the treatment of hyperglycemia, diabetes and obesity, as well as a variety of diseases or conditions associated with hyperglycemia, diabetes and obesity.Type: GrantFiled: February 24, 2015Date of Patent: November 8, 2016Assignee: Novo Nordisk A/SInventors: Jesper F. Lau, Thomas Kruse, Henning Thoegersen, Ulrich Sensfuss, Peter Kresten Nielsen
-
Patent number: 9486505Abstract: The present invention relates to novel glucagon peptides, to the use of said glucagon peptides in therapy, to methods of treatment comprising administration of said glucagon peptides to patients in need thereof, and to the use of said glucagon peptides in the manufacture of medicaments. The glucagon peptides of the present invention are of particular interest in relation to the treatment of hyperglycemia, diabetes and obesity, as well as a variety of diseases or conditions associated with hyperglycemia, diabetes and obesity.Type: GrantFiled: July 9, 2013Date of Patent: November 8, 2016Assignee: Novo Nordisk A/SInventors: Jesper F. Lau, Thomas Kruse, Henning Thoegersen, Ulrich Sensfuss, Peter Kresten Nielsen
-
Patent number: 9480753Abstract: The present invention relates to Fibroblast Growth Factor 21 (FGF21), more in particular to derivatives of FGF21 compounds having an albumin binder of the formula A-B-C-D-E- covalently attached. The invention also relates to novel FGF21 analogues, as well as to the pharmaceutical use of these FGF21 derivatives and analogues, in particular for the treatment of diabetes, dyslipidemia, obesity, cardiovascular diseases, metabolic syndrome, and/or Non Alcoholic Fatty Liver Disease (NAFLD). The derivatives of the invention are protracted, e.g. capable of maintaining a low blood glucose level for a longer period of time, capable of increasing the in vivo half-life of FGF21, and/or result in a lower clearance of FGF21. The derivatives of the invention are preferably furthermore of an improved oxidative stability.Type: GrantFiled: January 22, 2010Date of Patent: November 1, 2016Assignee: Novo Nordisk A/SInventors: Tina Møller Tagmose, Patrick William Garibay, Bírgítte Andersen, Henning Thøgersen, Birgit Wieczorek
-
Publication number: 20160271263Abstract: The present invention relates to novel peptide compounds which have an improved physical stability in solution and improved solubility at neutral pH, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of hyperglycemia, diabetes and obesity, as well as a variety of diseases or conditions associated with hyperglycemia, diabetes and obesity.Type: ApplicationFiled: May 16, 2016Publication date: September 22, 2016Inventors: Jesper F. Lau, Thomas Kruse, Lars Linderoth, Henning Thoegersen
-
Patent number: 9409966Abstract: The invention relates to protracted Glucagon-Like Peptide-1 (GLP-1) derivatives and therapeutic uses thereof. The GLP-1 derivative of the invention comprises a modified GLP-1(7-37) sequence having a total of 2-12 amino acid modifications, including Glu22 and Arg26, and being derivatised with an albumin binding residue or pegylated in position 18, 20, 23, 30, 31, 34, 36, 37, or 39. These compounds are useful in the treatment or prevention of diabetes type 2 and related diseases. The compounds are potent, stable, have long half-lives, a high affinity of binding to albumin, and/or a high affinity of binding to the extracellular domain of the GLP-1 receptor (GLP-1R), all of which is of potential relevance for the overall aim of achieving long-acting, stable and active GLP-1 derivatives with a potential for once weekly administration.Type: GrantFiled: October 3, 2014Date of Patent: August 9, 2016Assignee: Novo Nordisk A/SInventors: Jane Spetzler, Lauge Schaeffer, Jesper Lau, Thomas Kruse, Patrick W. Garibay, Steffen Reedtz-Runge, Henning Thoegersen, Ingrid Pettersson
-
Publication number: 20160129083Abstract: The invention relates to MIC-1 fusion proteins. More specifically it relates to compounds comprising fusion proteins comprising a MIC-1 protein or an analogue thereof at the C-terminus of the fusion protein and a functional variant of human serum albumin at the N-terminus of the fusion protein connected via a peptide linker. The compounds of the invention have MIC-1 activity. The invention also relates to pharmaceutical compositions comprising such compounds and pharmaceutically acceptable excipients, as well as the medical use of the compounds.Type: ApplicationFiled: January 19, 2016Publication date: May 12, 2016Inventors: Allan C. Shaw, Charlotte Helgstrand, Michael P. Bastner Sandrini, Sebastian B. Joergensen, Henning Thoegersen, Kristian Sass-Oerum, Sven Hastrup, Kim V. Andersen
-
Publication number: 20160102129Abstract: New GLP-1 derivatives, compositions thereof and their use in medicine.Type: ApplicationFiled: October 9, 2015Publication date: April 14, 2016Inventors: Steffen Reedtz-Runge, Ulrich Sensfuss, Thomas Kruse, Jane Spetzler, Henning Thoegersen, Christian W. Tornoee, Jesper F. Lau
-
Patent number: 9272019Abstract: The invention relates to MIC-1 fusion proteins. More specifically it relates to compounds comprising fusion proteins comprising a MIC-1 protein or an analog thereof at the C-terminus of the fusion protein and a functional variant of human serum albumin at the N-terminus of the fusion protein connected via a peptide linker. The compounds of the invention have MIC-1 activity. The invention also relates to pharmaceutical compositions comprising such compounds and pharmaceutically acceptable excipients, as well as the medical use of the compounds.Type: GrantFiled: June 17, 2015Date of Patent: March 1, 2016Assignee: Novo Nordisk A/SInventors: Allan Christian Shaw, Charlotte Helgstrand, Michael Paolo Bastner Sandrini, Sebastian Beck Joergensen, Henning Thoegersen, Kristian Sass-Oerum, Sven Hastrup, Kim Vilbour Andersen